Literature DB >> 1653903

A role for peptide in determining MHC class II structure.

S Sadegh-Nasseri1, R N Germain.   

Abstract

T lymphocytes recognize antigen-derived peptides associated with major histocompatibility complex (MHC) class I or class II proteins. Peptide is critical in class I heavy-chain folding and/or stable association with beta 2-microglobulin. Although data exist suggesting a relationship between class II structure and peptide association, no equivalent positive contribution of peptide to the folding state or stability of class II dimers has yet been demonstrated. We report here that most purified E alpha k E beta k molecules leaving low pH in the absence of specific peptide lack a compact, stable dimeric structure. Brief exposure to the appropriate peptide just before and during neutralization promotes this specific conformation in proportion to stably bound peptide, indicating that peptide is important in determining class II MHC structure. Our results also indicate that efficient generation of long-lived peptide-class II complexes involves two stages: initial peptide binding in an acidic environment, which enhances the ability of class II to enter a conformation, from which stabilization upon neutralization results in high-affinity binding of previously associated peptide.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653903     DOI: 10.1038/353167a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  73 in total

Review 1.  HLA-DM and the MHC class II antigen presentation pathway.

Authors:  P E Jensen; D A Weber; W P Thayer; X Chen; C T Dao
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Developmental plasticity of CNS microglia.

Authors:  L Santambrogio; S L Belyanskaya; F R Fischer; B Cipriani; C F Brosnan; P Ricciardi-Castagnoli; L J Stern; J L Strominger; R Riese
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

3.  Constitutive endocytosis and recycling of major histocompatibility complex class II glycoproteins in human B-lymphoblastoid cells.

Authors:  P A Reid; C Watts
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

4.  Increased proteolysis of diphtheria toxin by human monocytes after heat shock: a subsidiary role for heat-shock protein 70 in antigen processing.

Authors:  Barbara S Polla; Françoise Gabert; Brigitte M-N Peyrusse; Muriel R Jacquier-Sarlin
Journal:  Immunology       Date:  2006-11-20       Impact factor: 7.397

Review 5.  The convergent roles of tapasin and HLA-DM in antigen presentation.

Authors:  Scheherazade Sadegh-Nasseri; Mingnan Chen; Kedar Narayan; Marlene Bouvier
Journal:  Trends Immunol       Date:  2008-02-07       Impact factor: 16.687

Review 6.  Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease.

Authors:  P J Fairchild; C J Thorpe; P J Travers; D C Wraith
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

7.  Subtle conformational changes induced in major histocompatibility complex class II molecules by binding peptides.

Authors:  A V Chervonsky; R M Medzhitov; L K Denzin; A K Barlow; A Y Rudensky; C A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

8.  Superactivation of an immune response triggered by oligomerized T cell epitopes.

Authors:  O Rötzschke; K Falk; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

9.  Cloning of the gene encoding peptide-binding protein 74 shows that it is a new member of the heat shock protein 70 family.

Authors:  S Z Domanico; D C DeNagel; J N Dahlseid; J M Green; S K Pierce
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

10.  Biosynthesis of major histocompatibility complex molecules and generation of T cells in Ii TAP1 double-mutant mice.

Authors:  S Tourne; H M van Santen; M van Roon; A Berns; C Benoist; D Mathis; H Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.